You are here

  • Home
  • Archive
  • Volume 66, Issue 7
  • Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

Article info

Article menu

Download PDFPDF

XML
Hepatology
Original article
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

Authors

  • Julien Bollard Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Verónica Miguela Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Marina Ruiz de Galarreta Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Anu Venkatesh Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • C Billie Bian Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Mark P Roberto Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Victoria Tovar Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Daniela Sia Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Pedro Molina-Sánchez Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Christie B Nguyen Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Shigeki Nakagawa Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Josep M Llovet Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Yujin Hoshida Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Amaia Lujambio Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Amaia Lujambio, Department of Oncological Sciences, Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue 6-111, New York, NY 10029, USA; amaia.lujambio{at}mssm.edu
View Full Text

Citation

Bollard J, Miguela V, Ruiz de Galarreta M, et al
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
Gut 2017;66:1286-1296.

Publication history

  • Received May 16, 2016
  • Revised October 10, 2016
  • Accepted October 25, 2016
  • First published November 14, 2016.
Online issue publication 
June 06, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/